UniQure plans a first quarter 2026 FDA submission for AMT-130 as a treatment for Huntington’s disease. This gene therapy delivers microRNA designed to silence the mutated gene that produces a protein driving this disorder, which so far has no FDA-approved therapies.
The post UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become First Huntington’s Treatment appeared first on MedCity News.
